NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization43.3 mln
Float47.92 mln
Earnings Date08/13/2026
Piotroski F-Score
4
/ 9
Borderline
Relative Strength
100
/ 100
Top performer
Debt / Equity
2.31
Very high leverage
ROE
-139
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Werewolf Therapeutics is a drug development company focused on harnessing the body's immune system to fight cancer and other immune-related diseases. Founded in 2017 and based in Watertown, Massachusetts, the company uses its proprietary PREDATOR platform to create molecules that only become active in the right biological environment, making treatments more targeted and reducing unwanted side effects. Its pipeline includes several experimental therapies aimed at advanced cancers and inflammatory conditions such as inflammatory bowel disease.
